local_hospital

Bekes Varmegyei Koezponti Korhaz

Address
lock Available on a paid plan

Respiratory and Thoracic Oncology

At Bekes Varmegyei Koezponti Korhaz in Gyula, a major share of research focuses on respiratory tract diseases and neoplasms, especially non-small cell lung cancer and related advanced lung tumors. These studies are designed to test new treatment approaches, compare them with current standards, and improve survival outcomes for people with difficult-to-treat cancers.

  • Non-small cell lung cancer and advanced lung cancer
  • Stage IV, metastatic, and PD-L1–positive disease
  • Evaluating new cancer therapies and combinations against established care

The site’s pulmonary department supports a broad oncology portfolio, with research aimed at better disease control, longer progression-free survival, and improved overall outcomes.

Breast and Prostate Cancer Research

The clinical trial program includes extensive work in breast cancer and prostate cancer, covering both early and advanced disease. Studies are exploring new endocrine-based strategies, targeted treatments, and combination approaches to reduce recurrence and improve disease control in hormone-driven cancers.

  • ER-positive, HER2-negative breast cancer
  • Metastatic breast cancer and high-risk early-stage disease
  • Prostate cancer, including metastatic castration-resistant and high-risk localized disease

Research at the site includes efforts to prevent recurrence, delay progression, and identify more effective options for patients whose cancer has returned or spread.

Autoimmune and Inflammatory Diseases

A strong portion of the research landscape centers on immune system diseases and chronic inflammatory conditions such as systemic lupus erythematosus, psoriatic arthritis, rheumatoid arthritis, and Sjögren’s syndrome. These trials are mainly aimed at improving symptom control, reducing disease activity, and assessing the long-term safety of newer immune-modulating treatments.

  • Systemic lupus erythematosus and related systemic autoimmune disease
  • Psoriatic arthritis and rheumatoid arthritis
  • Sjögren’s syndrome and other immune-mediated disorders

This area reflects a broad interest in therapies that may help patients live with fewer flares, less inflammation, and better daily function.

Cardiovascular and Metabolic Medicine

The site also conducts research in cardiovascular diseases and nutritional and metabolic diseases, including heart failure, acute myocardial infarction, hyperlipidaemia, and type 2 diabetes. These studies are focused on lowering cardiovascular risk, improving heart function, and testing whether newer therapies can better support long-term prevention and treatment.

  • Heart failure and inflammation-related cardiac disease
  • Acute myocardial infarction and prevention of recurrent events
  • Hyperlipidaemia and type 2 diabetes

Research in this field aims to reduce serious complications such as heart attack, stroke, and worsening heart failure while improving everyday disease management.

Infectious, Liver, and Surgical Care

Clinical trials at the hospital cover bacterial infections, virus diseases, and selected digestive system diseases, including chronic hepatitis B and primary biliary cholangitis. There is also work on preventing surgical infections and supporting safer care around urgent procedures.

  • Chronic hepatitis B and liver-related disease
  • Post-surgical infection prevention
  • Bacterial pneumonia and other serious infections

These studies are intended to improve infection control, support recovery after surgery, and explore better options for chronic liver conditions with ongoing symptoms.

Additional Chronic Disease and Symptom-Focused Research

Beyond the main specialty areas, Bekes Varmegyei Koezponti Korhaz participates in trials across a wide range of chronic conditions, including chronic obstructive pulmonary disease, chronic kidney disease, pruritus, and selected mental disorders in children and adolescents. The aim is often to improve symptom relief, strengthen disease control, or assess whether new therapies can offer better everyday outcomes.

  • COPD and other chronic respiratory conditions
  • Chronic kidney disease and multisystem inflammatory disease
  • Pruritus and symptom-driven quality-of-life research

This mix of studies shows a broad clinical research profile that extends beyond one specialty, with attention to both complex diseases and patient-reported symptoms.

Site Overview

assignment
130
connected trials
corporate_fare
59
sponsors
science
189
IMPs

Activity Indicator

Last 6 months

16
Trials started
0% vs previous period.
16
Trials started 6–12 months ago
130
Total trials linked
Highly Active
trending_flatStable0%
4
3
5
2
2
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status

Top 4 of 18 therapeutic areas and 15 of 189 IMPs, ranked by number of trials.

lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years

Top 40 of 184 compounds, ranked by number of trials.

lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
59
Sponsors (total)
59
Active sponsors
34

Sponsor Network

Top 34 by active trials.

lock +33 more on a paid plan

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

lock +21 more on a paid plan

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 332 other sites in Hungary

description
Trial volume
130
Outperforms 98% of sites
public
Therapeutic diversity
18areas
Outperforms 99% of sites
groups
Sponsor diversity
59sponsors
Outperforms 99% of sites

Therapeutic Area Benchmark — Hungary

Select a therapeutic area to compare against other sites in Hungary.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: Hungary

Market Share

Country: Hungary

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Bekes Varmegyei Koezponti Korhaz

lock Showing 1 of 130 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
A Multi-Center Study to Characterize the Long-Term Safety and Efficacy of BMS-986165 in Subjects with Systemic Lupus ErythematosusBristol Myers Squibb International CorporationPhase IINot RecruitingMay 2019Mar 2025

IMP list

lock Showing 1 of 189 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Pembrolizumab11Unknown2018-08-242026-06-01

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.